News Releases

These are news releases that are related to our company, pipeline and investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.

Jan 13, 2022

Summary Toggle aTyr Pharma Advances Development of Lead Therapeutic Candidate ATYR1923 with Announcement of “efzofitimod” as Nonproprietary Name

Efzofitimod expected to enter into a registrational trial for pulmonary sarcoidosis in 2022 SAN DIEGO , Jan. 13, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways,
Jan 6, 2022

Summary Toggle aTyr Pharma Announces FDA Orphan Drug Designation for ATYR1923 for Treatment of Sarcoidosis

Company expects to initiate registrational trial of ATYR1923 in pulmonary sarcoidosis in 2022 SAN DIEGO , Jan. 06, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel
Jan 4, 2022

Summary Toggle aTyr Pharma to Present at H.C. Wainwright Virtual BioConnect Conference

SAN DIEGO , Jan. 04, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Jill Broadfoot , Chief Financial Officer, will present a corporate
Dec 24, 2021

Summary Toggle aTyr Pharma Appoints Danielle Campbell as Vice President of Human Resources

SAN DIEGO , Dec. 24, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment of Danielle Campbell to Vice President, Human Resources. Ms.
Dec 10, 2021

Summary Toggle aTyr Pharma to Present at Antibody Engineering & Therapeutics Conference

Novel engineering approach accelerates generation of new antibody candidates from tRNA synthetase platform. SAN DIEGO , Dec. 10, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel
Nov 30, 2021

Summary Toggle aTyr Pharma and FUJIFILM Diosynth Biotechnologies Announce Manufacturing Agreement for aTyr’s Lead Therapeutic Candidate ATYR1923

SAN DIEGO , Nov. 30, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, and FUJIFILM Diosynth Biotechnologies, a leading contract development and manufacturing
Nov 12, 2021

Summary Toggle aTyr Pharma to Present at Upcoming Investor Conferences in November

SAN DIEGO , Nov. 12, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla , M.D., M.S., President and Chief Executive Officer,
Nov 10, 2021

Summary Toggle aTyr Pharma Announces Third Quarter 2021 Results and Provides Corporate Update

Positive results reported from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis provided proof-of-concept for ATYR1923 and validation for tRNA synthetase biology platform and NRP2 target. Registrational trial for ATYR1923 in pulmonary sarcoidosis expected to initiate in 2022.
Nov 9, 2021

Summary Toggle aTyr Pharma Presents Research Demonstrating Effects of Novel NRP2-Targeting Antibody, ATYR2810, on Tumor Associated Macrophages at the Society for Immunotherapy of Cancer Annual Meeting

Findings provide key insights into ATYR2810’s potential mechanism of action, including ability to modulate key immune cells involved in tumor progression, metastasis and therapy resistance. Data will support the clinical development of ATYR2810, including a Phase 1 study in cancer next year.
Nov 3, 2021

Summary Toggle aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2021 Financial Results

Management to host conference call and webcast on November 10th at 5:00 pm EST / 2:00 pm PST SAN DIEGO , Nov. 03, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways,